 NEW YORK, April 26, 2021 GLOBE NEWSWIRE -- Anavex Life Sciences Corp. Anavex or the Company Nasdaq: AVXL, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system CNS disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the B. Riley Securities Virtual Neuroscience Conference on Wednesday, April 28, 2021 at 12:00 p.m. EDT. 